MorphoSys AG (MOR) Given a €76.00 Price Target by Commerzbank Ag Analysts
MOR has been the subject of several other research reports. Independent Research GmbH set a €77.00 ($91.67) price objective on MorphoSys AG and gave the company a buy rating in a report on Monday, May 29th. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price objective on MorphoSys AG and gave the company a neutral rating in a report on Thursday, September 7th. Berenberg Bank set a €68.00 ($80.95) price objective on MorphoSys AG and gave the company a buy rating in a report on Thursday, May 25th. J P Morgan Chase & Co restated a neutral rating on shares of MorphoSys AG in a report on Monday, July 17th. Finally, HSBC Holdings plc set a €59.00 ($70.24) price objective on MorphoSys AG and gave the company a neutral rating in a report on Friday, July 14th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of €71.00 ($84.52).
Shares of MorphoSys AG (ETR MOR) opened at 70.649 on Thursday. The firm’s market cap is €2.05 billion. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €70.90. The firm has a 50 day moving average price of €60.74 and a 200-day moving average price of €59.75.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/24/morphosys-ag-mor-given-a-76-00-price-target-by-commerzbank-ag-analysts-2.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.